- Matica Biolabs has signed a contract manufacturing agreement with Jeongjin Bioscience to produce mesenchymal stem cell-conditioned media for skin regeneration applications.
- The company also entered a collaboration with CRO firm Humic to develop integrated CDMO and CRO services across the biopharmaceutical development lifecycle.
Matica Biolabs, a subsidiary of CHA Biotech, has entered into a contract manufacturing agreement with Jeongjin Bioscience to produce mesenchymal stem cell-conditioned media. The materials will be used by Jeongjin Bioscience in the development of medical devices for skin regeneration.
Under the agreement, Matica Biolabs will manufacture and supply stem cell-conditioned media containing bioactive substances secreted during stem cell culture, including growth factors, antioxidants, and cytokines. The partnership expands the company’s role in cell and gene therapy-related contract manufacturing activities.
Separately, Matica Biolabs signed a memorandum of understanding with Humic, a contract research organization specializing in non-clinical and clinical services. The companies plan to develop integrated CDMO and CRO services covering areas such as process development, efficacy and toxicity testing, production of non-clinical samples, and regulatory support.
The agreements were finalized during BIO KOREA 2026, held at COEX in Seoul. According to the company, the partnerships are intended to strengthen collaboration opportunities across the biopharmaceutical development lifecycle.
“Building on more than 20 years of biopharmaceutical R&D and manufacturing experience accumulated by the CHA Bio Group, we will continue to expand our support in production and quality to help our clients’ technologies reach the market.”
Min Byung-jo, CEO of Matica Biolabs
